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The nature of the biopharmaceutical sector is such that new scientific and 
product ideas originate from university biomedical research laboratories. Innovations in 
the biopharmaceutical sector are heavily dependent on knowledge/technology transfer 
relationships between academic research and industrial actors (firms). The dominant 
channels of university/industry knowledge and technology transfer include licensing of 
technologies, research collaboration and the formation of spin-offs. Technology transfer 
offices facilitate licensing and movement of innovations from university labs to 
companies. In the interest of strengthening and facilitating university/industry 
technology transfer particularly in the biomedical field, academic patenting and licensing 
have gained prominence globally following the passing of the Bayh Dole Act (1980) in 
the United States of America (USA) and similar legislation in other countries.  
 
Research Question 
The South African biopharmaceuticals sector is characterized by a paradox 
whereby on one hand the country possesses a robust biomedical knowledge 
production/research system but a failure in the uptake of locally produced knowledge 
and the application of the same in production (innovation). One way in which South 
African policy seeks to address this paradox is by formulating a framework for 
intellectual property (IP) protection for publicly funded research modeled along the 
American Bayh Dole Act. This paper investigates the role of academic patenting and 
licensing in addressing the paradox. The paper examines 2 broad factors considered to be 
critical in understanding learning and innovation processes between academia and 
industry namely the nature of interactions between university and industry and the relation between 
university research and clinical application. The paper tries to understand the reason why 
university/industry linkages in the biomedical field are weak in South Africa and how 
they can be used in a meaningful way beyond providing student attachments. The paper 
investigates whether firms utilize university research as a source of knowledge for their 
innovation activities which is a critical factor in establishing whether there is a market for 
the knowledge being produced at universities. Lastly, we investigate what types of 
biomedical research is conducted and how research themes in universities were selected 
and the factors that influenced research priority setting and whether university research is 
aligned to what the South African biopharmaceutical industry finds interesting and 
whether any of the knowledge being produced targets any of the main health concerns in 
South Africa, mainly HIV/AIDS, TB, Malaria?  
 
Research Design and Description of Data 
The data used in this paper is derived from multiple sources. We use publication 
data from the Science Citation Index Expanded (SCI Expanded) database, which reviews 
more than 6,000 peer-reviewed journals for the period between 1991-2002, that are 
considered as the most important in their respective fields, within 2 broad categories 
namely, biomedical sciences and clinical medicine. The journals included in this database 
reflect significant scientific achievements and are the most widely cited journals globally 
using an average relative impact factor and average relative citation index. The analysis 
covers publications by South African authors and establishes the robust nature of 
biomedical research and knowledge production in South Africa. From the SCI Expanded 
database, we also identified the top 20 publishing biomedical researchers and interviewed 
them using an open-ended semi structured questionnaire to elicit information regarding 
the incentive structure for biomedical research at universities and regarding their attitudes 
and perceptions towards academic patenting and licensing in promoting biomedical 
research and innovation and their perceptions of the role of university TTOs and their 
experiences 
 
We also surveyed technology transfer offices (TTO) at the country’s 5 main 
universities namely the University of Cape Town, Stellenbosch University, University of 
Pretoria, Witwatersrand and KwaZulu Natal. These Universities produce approximately 
85.5% of all the scientific publications output according to publications data on the SCI 
Expanded database. In surveying these technology transfer offices we used an open-
ended semi-structured questionnaire which was structured and designed to elicit 
information concerning the following: 
 main functions of TTO offices,  
 the rules for disclosure by faculty of potentially commercializable research 
 features of respective university IPR policies that allow for such 
disclosure,  
 university biomedical patent portfolios,  
 the existence of license agreements which allow for the use of IP by 
private sector firms and  
 the presence of spin-off companies from universities 
 
We then conducted a firm level survey by use of a structured closed-ended 
questionnaire. The questionnaire was designed to elicit information on the role of patents 
and licensed knowledge in learning and innovation process in firms. We also gathered 
information regarding the importance firms attach to patents as a method of 
appropriation and also as a source of knowledge for their research and as a means of 
keeping abreast with technological trends. 
 
Preliminary Results 
This paper shows growth and expansion of biomedical research and knowledge 
production at South African universities. At the same time the paper shows that 
university/industry linkages are weak and that the South African biopharmaceutical 
sector is characterized by very low patenting and licensing activity both at universities 
and firms. Academic patenting and licensing is not the primary channel of technology 
transfer and knowledge exchange with industry. University TTOs lack skilled and 
experienced technology transfer professionals and are faced with grave financial 
constraints, in light of decreasing government subsidies to universities. Most TTOs are 
understaffed and lack the necessary expertise, for instance the ability to analyze invention 
disclosures. There exists a poor perception of the role of TTOs by scientist characterized 
by mistrust which needs to be addressed.  
 
The paper shows very interesting results regarding biopharmaceutical firms’ 
patenting behavior in South Africa. Firms prefer to use marketing related methods of 
appropriation, such as first to market, trade secrecy and trademarks. By the places where 
firms choose to register their patents, firms target both local and foreign markets. The 
diseases covered by these patents have both local and global applications such as 
HIV/AIDS and cancer. Another very interesting observation is that all patenting firms 
except one had made a product out of their patented knowledge. This high rate of 
conversion from patent to product by firms seems to suggest that South African firms 
tend to take out mature patents and only when there is actual promise of commercial 
success. 
 
Despite university aligning its research to local healthcare needs a gap appears in 
the fact that the industrial sector is not strong enough to provide a market for the 
university research. Industry in most cases does not utilize what is published by academic 
researchers and thus these 2 actors relate at a very superficial level.  It is observed that 
licensing-in positively affects R&D performance and firm innovativeness. It is also 
observed that licensing-in firms, licensed knowledge from abroad. The same preference 
is observed with licensing out firms, where only one firm licensed its knowledge to a 
local firm. This observation calls for further investigation as to whether what was 
licensed in was available at local universities or not and if so, why did firms not license 
from universities? 
 
The formulation of a new national IP policy framework for publicly funded 
research in South Africa without undertaking structural reforms in the university system 
and without adequate awareness creation among biomedical researchers is likely to 
accomplish little or could very well be counterproductive. For example a lot of work 
remains to be done to overcome the resistance and negative perception of IP from 
biomedical researchers. There is also a need to review the current university incentive 
structure which is based on publications, student supervision and prestige arising from 
recognition by agencies such as the NRF. For the proposed IP policy framework for 
publicly funded research to work,  funding agencies such as NRF and THRIP will need 
to introduce a new criteria for funding focusing on the funding more applied research 
with a potential for commercial application. The current funding requirement does not 
require researchers to show the potential commercial application of their research. 
 
We conclude that due to an interplay of factors such as the infancy of the sector, 
the incentive structure for biomedical research scientists, which is geared towards 
rewarding publishing of journal articles and teaching (leading to a poor perception of IP 
by research scientists) and a poor IP support infrastructure, academic patenting and 
licensing do not yet really have a critical role in fostering learning and innovation in the 
current status of the South African biopharmaceutical sector. Due to the nascent nature 
of the sector in South Africa, intellectual property, particularly patents and licensing, as a 
tool for fostering learning and innovation is not yet playing a prominent role. It is likely 
that with the introduction of the new IP policy framework for publicly funded research, 
university researchers will get sensitized about patents and their role in respect of their 
research results. It also likely that with the new IP policy framework, more funding will 
be allocated for creating and strengthening capacities at university technology transfer 
offices.  
